AbbVie to Discontinue its P-III MERU Trial of Rovalpituzumab Tesirine (Rova-T) as 1L Maintenance Therapy for Patients with Advanced Small-Cell Lung Cancer

 AbbVie to Discontinue its P-III MERU Trial of Rovalpituzumab Tesirine (Rova-T) as 1L Maintenance Therapy for Patients with Advanced Small-Cell Lung Cancer

AbbVie Resolves Humira (adalimumab) Litigation with Boehringer Ingelheim

Shots:

  • The Independent Data Monitoring Committee (IDMC) recommends for the termination of P-III MERU trial due to lack of survival benefits for patients receiving Rova-T vs PBO control arm based on results at a pre-planned interim analysis
  • The P-III MERU trial is discontinued with the closure of R&D program for Rova-T and the trial involves assessing of Rova-T as maintenance therapy following 1L platinum-based chemotherapy in patients with advanced SCLC evaluating its safety and efficacy
  • Rova-T is an investigational ADC targeting cancer-stem cell-associated delta-like protein 3 (DLL3). Additionally, AbbVie oncology portfolio is evaluated in 300+ trials and in more than 20 different tumor type

Click here to read full press release/ article | Ref: AbbVie| Image: Signbox

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post